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Abstract
Background:  Activins stimulate pituitary FSH synthesis via transcriptional regulation of the
FSHbeta subunit gene (Fshb). Like other members of the TGFbeta superfamily, these ligands signal
through complexes of type I and type II receptor serine/threonine kinases. The type I receptors,
or activin receptor-like kinases (ALKs), propagate intracellular signals upon ligand binding and
phosphorylation by associated type II receptors. ALK4 is generally regarded as the type I receptor
for activins; however, recent data suggested that activin B and AB might also signal through ALK7.
Here, we examined a role for ALK7 in activin B-regulated Fshb transcription.
Methods: We analyzed ALK7 mRNA expression in immortalized gonadotrope cells, LbetaT2, and
adult murine pituitary by RT-PCR. We next transfected LbetaT2 cells with wild-type and kinase-
deficient (Lys to Arg, KR) forms of ALK4 and ALK7 and examined the effects of these receptors
on activin A and B stimulated Fshb promoter-reporter activity. Cells were also transfected with
constitutively active (Thr to Asp, TD) forms of the receptors and their effects on endogenous Fshb
mRNA levels and phosphorylation of transfected Smad2/3 were measured by RT-PCR and
Western blot, respectively. Finally, we measured ALK4(TD) and ALK7(TD) stimulation of Fshb
transcription when endogenous Smad3 levels were depleted using short hairpin RNAs.
Results: ALK7 mRNA was expressed in LbetaT2 cells and pituitary gland. Transfection of ALK4
cDNA potentiated the effects of both activin A and activin B on Fshb promoter-reporter activity
in LbetaT2 cells. In contrast, ALK7 transfection selectively potentiated activin B's effects.
Transfection of ALK4(KR) and ALK7(KR) partly inhibited basal and activin B-stimulated reporter
activity, whereas ALK4(TD) and ALK7(TD) potently stimulated the Fshb promoter and
endogenous mRNA levels. Transfection of both ALK4(TD) and ALK7(TD) stimulated Smad2/3
phosphorylation, and the effects of both receptors on Fshb promoter activity were inhibited by
depletion of endogenous Smad3 protein levels.
Conclusion: These data suggest that immortalized gonadotropes express ALK7 and that activin B
can signal through this receptor to stimulate Fshb transcription. The relative roles of endogenous
ALK4 and ALK7 receptors in mediating activin B's effects in these cells have yet to be determined.
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Background
Activins were first isolated from porcine follicular fluid
during the purification of the inhibins and were shown to
have potent and selective stimulatory effects on pituitary
FSH secretion [1,2]. Their effects are largely mediated via
up-regulation of FSHβ (Fshb) subunit gene transcription
[3-5]. Unlike the inhibins which function as gonadally-
derived endocrine hormones, activins in the circulation
are bound to follistatins and are therefore biologically
inactive [6,7]. However, the activin subunits are expressed
in adult pituitary gland, suggesting that activins can be
produced locally and may function as paracrine or auto-
crine regulators of FSH production by gonadotropes cells.
Indeed, the activin βB subunit (INHBB) is produced by rat
gonadotropes in vivo and immortalized murine gonado-
trope cells (LβT2) [5,8,9], and its immunoneutralization
inhibits FSH release from rat pituitary cell cultures [10]. In
contrast, the activin βA subunit (INHBA) is expressed
throughout the pituitary, though not in LβT2 cells, and
INHBA subunit bio-neutralizing antibodies have no effect
on FSH secretion [8-10]. These data suggest that activin B
(a homodimer of INHBB subunits) is the physiologically
relevant activin family member in the pituitary.
TGFβ superfamily proteins produce their effects in target
cells by binding complexes of type I and type II receptor
serine/threonine kinases [11,12]. For activins, the ligand
binding type II receptors are ACVR2A and ACVR2B
[13,14]. Once bound, these receptors phosphorylate the
type I receptor, activin receptor-like kinase 4 (ALK4;
ACVR1B), in a juxtamembrane domain called the GS box
[15,16]. This activates the type I receptor, allowing it to
phosphorylate intracellular effectors such as the Smads. A
second type I receptor, ALK2 (also known as ACVR1), was
shown to bind activin A, but does not appear to transduce
the ligand's intracellular signals [15,17,18]. Thus, ALK4
has conventionally been considered the only type I recep-
tor for the activins.
This notion was recently challenged by the observation
that another type I receptor, ALK7 (ACVR1C), could prop-
agate activin B and activin AB signals in a murine pancre-
atic β cell line [19]. Interestingly, the receptor appeared
insensitive to activin A, suggesting that unique features of
the INHBB subunit [20] permit its association with this
receptor. Given activin B's purported role in FSH regula-
tion, we examined whether the ligand could signal




Human recombinant (rh-) activin A and activin B were
purchased from R&D systems (Minneapolis, MN). Rat
ACVR1 (ALK2)-HA and rat ACVR1B (ALK4)-HA expres-
sion vectors were generously provided by Dr. T. Woodruff
(Northwestern University, Evanston, IL). Wild-type and
constitutively active (T194D) human ACVR1C (ALK7)-
myc/His constructs were gifts from Dr. C. Peng (York Uni-
versity, Toronto, Canada). Constitutively active
ALK4(T206D)-HA, kinase-deficient ALK4(K234R)-HA,
and kinase-deficient ALK7(K222R)-myc/His were gener-
ated by site-directed mutagenesis. Human Flag-Smad2
and human Flag-Smad3 were provided by Dr. E. Rober-
ston (Oxford University, UK) and Dr. Y. Chen (Indiana
University), respectively. All expression constructs con-
tained the CMV promoter, except for Flag-Smad2, which
was in a modified pCAGGS vector [21,22]. The -1990/+1
mFshb-luc reporter construct and Smad3  shRNA vector
were described previously [3].
Cell culture, transfections, and luciferase assays
Immortalized mouse gonadotrope LβT2 cells were pro-
vided by Dr. Pamela Mellon (University of California, San
Diego). Cells used in luciferase assays were seeded in 24-
well plates and transfected with Lipofectamine 2000 (Inv-
itrogen, Carlsbad, CA) as previously described [3,22].
Luciferase assays were performed on a Luminoskan Ascent
luminometer (Thermo Labsystems, Franklin, MA) using
standard reagents. All treatments were performed in
duplicate or triplicate, and each experiment repeated two
or three times as indicated. For RNA analysis of cells trans-
fected with constitutively active receptors, cells were
seeded in 6-well plates and transfected for 6 h with 1 μg of
expression plasmid using Lipofectamine/Plus (Invitro-
gen). After 24 h incubation in growth medium, total RNA
was isolated using Trizol (Invitrogen).
Reverse transcriptase PCR
ALK7 and Fshb mRNA expression in adult male C57BL6/J
mouse pituitary, adult male CD-1 mouse brain and LβT2
cell DNased total RNA were examined by RT-PCR using
the following primer sets and previously described meth-
ods [3]: ALK7. for, ATGACCCCAGCGCGCGGCTCCG-
CACT; ALK7. rev, CTTCCTGTATGTGCACTGGCGGTCCT;
Fshb. for, ATGAAGTTGATCCAGCTTTG; Fshb. rev, CATT-
TCACTGAAGGAGCAGT. RNA was extracted using Trizol.
Immunoblot
LβT2 cells in 6-well plates were transfected for 6.5 hr with
0.9 μg/well ALK4(TD) or ALK7(TD) along with 2 μg/well
pcDNA3, Flag-Smad2, or Flag-Smad3 using Lipo-
fectamine/Plus (Invitrogen). After approximately 18 h,
whole cell extracts were prepared in RIPA buffer. Equiva-
lent amounts of protein (20 μg/lane) were separated by
SDS-PAGE on a 7% Tris acetate gel (NuPage, Invitrogen)
and transferred to a Protran nitrocellulose filter (Sch-
leicher & Schuell, Keene, NH). The blot was probed with
the following antibodies using standard techniques: phos-
pho-Smad2 (Cell Signaling Technology, Danvers, MA),Reproductive Biology and Endocrinology 2006, 4:52 http://www.rbej.com/content/4/1/52
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phospho-Smad3 (gift of Dr. M. Reiss, UMDNJ-RWJMS),
Flag M2 and β-actin (Sigma, St. Louis, MO) HRP conju-
gated secondary antibodies were from Biorad (Hercules,
CA) and ECL Plus reagents from GE Healthcare.
Statistics
Treatments were performed in duplicate or triplicate, and
each experiment repeated two or three times as indicated
in the figure legends. Replicates within individual experi-
ments were averaged and these values used in statistical
analyses. Effects of the different manipulations were
assessed with two-way analyses of variance (ANOVA) as
described in the Results, and post-hoc comparisons of sig-
nificant main effects or interactions were made using
Fisher's LSD procedure. In all cases, significance was
assessed relative to p < 0.05.
Results
ALK7 is expressed in pituitary gland and LβT2 cells
We used RT-PCR to examine ALK7 mRNA expression in
adult murine pituitary gland and immortalized LβT2
gonadotrope cells. ALK7 was first identified in rat brain
[23,24]. Therefore, adult murine brain was used as a pos-
itive control. ALK7 mRNA was detected in all three sam-
ples (Fig. 1).
ALK7 potentiates activin B signaling in LβT2 cells
Next, we transfected LβT2 cells with a murine Fshb pro-
moter-reporter construct [3] along with expression vectors
encoding wild-type ALK2, ALK4 or ALK7, followed by
treatment with 25 ng/ml activin A or activin B for 24 h
(Fig. 2A). Two-way ANOVA showed significant effects of
ligand and receptor, and a significant interaction between
the two variables. Post-hoc analysis revealed that activin A
was more potent than activin B, as we have seen previ-
ously [9], and that ALK4 transfection had the most signif-
icant stimulatory effect of the three receptors examined.
ALK7 differed significantly from ALK2-, but not pcDNA3-
transfected cells. Pair-wise comparisons of the significant
interaction showed that in the presence of transfected
ALK4, the activity of both ligands was increased, though
activin A was still more potent than activin B. ALK7 trans-
fection had no effect on the activin A response, but
enhanced activin B activity (Fig. 2A, arrowhead); however,
the potentiation with exogenous ALK7 was less than that
observed with ALK4. In the context of the entire analysis,
ALK2 did not have a statistically significant effect. How-
ever, when the analysis was restricted to ALK2- versus
pcDNA3-transfected cells (i.e., with data for ALK4 and
ALK7 omitted), ALK2 significantly suppressed reporter
activity (main effect of receptor) and inhibited the activin
A response relative to control.
Kinase-deficient forms of ALK4 and ALK7 inhibit basal and 
activin B regulated transcription
Previous data suggest that endogenous activin B signaling
may regulate "basal" Fshb expression in LβT2 cells [5,9].
As an additional means to assess type I receptor function,
ALK7 is expressed in LβT2 cells Figure 1
ALK7 is expressed in LβT2 cells. ALK7 mRNA expression was analyzed by RT-PCR in adult mouse pituitary and brain, and 
in LβT2 cell RNA. RT+ and RT- indicate that reverse transcriptase enzyme was included or omitted, respectively, during the 
cDNA synthesis step. The H2O sample confirmed that none of the reagents were contaminated.Reproductive Biology and Endocrinology 2006, 4:52 http://www.rbej.com/content/4/1/52
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ALK7 can potentiate activin B signaling Figure 2
ALK7 can potentiate activin B signaling. A, LβT2 cells seeded in 24-well plates were transfected with 450 ng/well pro-
moter-reporter and 200 ng/well of the indicated receptor expression vector. Cells were then treated with 25 ng/ml activin A 
or B in serum-free medium for 24 h. Cell lysates were collected and assayed for luciferase activity. Data are presented as fold 
difference from the control condition (pcDNA3, Control) set to 1 and represent the mean (± s.d.) of three independent 
experiments performed in duplicate. The arrowhead shows the potentiation of the activin B response in the presence of ALK7. 
B, Cells were transfected with kinase-deficient forms (KR) of ALK4 and ALK7 alone and treated with activin B as described in 
A. Data are from two independent experiments with treatments performed in triplicate. In both panels, bars with different let-
ters differed significantly from one another.
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we transfected expression constructs encoding kinase-
deficient forms of ALK4 (K234R) and ALK7 (K222R) and
then treated cells with activin B. These receptors can bind
ligand, but do not propagate intracellular (Smad-depend-
ent) signals and therefore act as dominant-negative regu-
lators [25,26]. Two-way ANOVA revealed significant
effects of ligand, receptor, and the interaction. Post-hoc
comparisons showed that overall both ALK4(KR) and
ALK7(KR) significantly diminished Fshb reporter activity
(Fig. 2B). Pair-wise comparisons of the interaction
showed that ALK4(KR) diminished basal reporter activity,
and both receptors significantly inhibited the effects of
activin B.
ALK7 stimulates Fshb expression through a Smad-
dependent pathway
To confirm that signaling events downstream of ALK7 reg-
ulate endogenous Fshb expression, we transfected LβT2
cells with constitutively active forms of ALK4 (T206D)
[26] and ALK7 (T194D) [25]. We previously showed that
ALK4(TD) stimulated Fshb expression in these cells in the
absence of exogenous ligand or co-transfected type II
receptors [3]. Here, both transfected ALK4(TD) and
ALK7(TD) stimulated endogenous Fshb mRNA levels (Fig.
3A) and murine Fshb promoter-reporter activity (Fig. 4,
see white bars).
The L45 loops of ALKs 4, 5, and 7 are identical and it is
through this sub-domain that these three receptors inter-
face with the intracellular signaling proteins Smads 2 and
3 [27]. We first confirmed that the two receptors could
stimulate Smad2 and Smad3 phosphorylation in LβT2
cells. Cells were transfected with ALK4(TD) or ALK7(TD)
and Flag-Smad2 or Flag-Smad3. Immunoblots showed
that both Smads were phosphorylated by both receptors
(Fig. 3B). Smads transfected in this manner in the absence
of constitutively active receptors were not phosphorylated
(data not shown).
We previously showed that ALK4(TD) signals through
both of these Smads to regulate murine Fshb [3]. To deter-
mine if ALK7(TD) similarly uses a Smad-dependent path-
way in these cells, we depleted intracellular Smad3
protein levels with a validated Smad3  shRNA [3] and
measured -1990/+1 mFshb-luc activity in response to
transfected ALK4(TD) or ALK7(TD) (Fig. 4). Two-way
ANOVA showed a significant effect of receptor, with
ALK7(TD) stimulating reporter activity more than
ALK4(TD), as well as a significant inhibitory effect of the
Smad3 knock-down. Pair-wise comparisons of the signif-
icant interaction showed that transfection of the Smad3
shRNA inhibited the effects of both receptors to compara-
ble extents [39 and 46% for ALK4(TD) and ALK7(TD),
respectively], without affecting basal activity of the pro-
moter in cells transfected with the empty expression vec-
tor (pcDNA3).
Discussion
Within the TGFβ superfamily, there are a total of seven
type I receptors, commonly referred to as ALKs 1–7 [28].
Although individual ligands are known to signal through
different type I receptors in different contexts [29], ALK4
was previously considered the only type I receptor used by
the activins. Recently, however, activin B and activin AB
where shown to signal through ALK7 in a murine pancre-
atic β cell line [19]. Here, we show that ALK7, like ALK4,
mRNA is expressed in both adult murine pituitary gland
and immortalized murine gonadotrope cells, LβT2.
Importantly, we further demonstrate that this receptor can
broker activin B, but not activin A, signaling in this cell
type. Given that activin B appears to be the physiologically
relevant activin family member in the pituitary [8,10],
these results may uncover a heretofore unappreciated
mechanism of Fshb gene regulation.
Despite its clear ability to transduce activin B signals,
transfected ALK7 was less effective than ALK4 in potenti-
ating the ligand's effects. It is therefore possible that
activin B may have a higher affinity for ALK4 than for
ALK7. Unfortunately, because the type II receptors are the
high affinity binding sites for activins, it is difficult to
directly assess relative type I receptor affinities [30]. None-
theless, our data are consistent with the notion that affin-
ity differences might be involved. Not only does wild-type
ALK4 potentiate activin B signaling to a greater extent than
wild-type ALK7, but the kinase-deficient form of ALK4 is
also more efficient in inhibiting both endogenous (basal)
and exogenous activin B signaling. Nonetheless, because
the constructs used here had different epitope tags, we
were unable to measure relative levels of expression of the
two receptors and therefore cannot rule out the possibility
that expression level contributed to the observed results.
However, constitutively active ALK7(TD) was equivalent
to or more potent than ALK4(TD) in stimulating endog-
enous Fshb expression and Fshb promoter activity. Given
that all three ALK7 constructs (wild-type, KR, and TD)
were created in the same expression vector, we do not
believe that lower ALK7 wild-type or KR receptor expres-
sion completely accounts for their lesser effects on activin
B-mediated signaling.
Mechanisms whereby ALK4 and ALK7 regulate Fshb pro-
moter activity appear to be conserved. We and others
noted previously that depletion of intracellular Smad3
protein levels by RNA interference inhibits, but does not
completely block, ALK4(TD)- or activin A-dependent reg-
ulation of Fshb [3,22,31]. The same pattern of results is
observed here with ALK7(TD). These data suggest that
activin B signaling via ALK4 or ALK7 can use both Smad3-Reproductive Biology and Endocrinology 2006, 4:52 http://www.rbej.com/content/4/1/52
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Constitutively active forms of ALK4 and ALK7 stimulate Fshb mRNA expression and Smad2/3 phosphorylation Figure 3
Constitutively active forms of ALK4 and ALK7 stimulate Fshb mRNA expression and Smad2/3 phosphoryla-
tion. A, LβT2 cells were transfected as described with constitutively active (TD) forms of ALK4 and ALK7. RNA was isolated 
and Fshb mRNA levels measured by RT-PCR. Rpl19 was used as a loading control. B, LβT2 cells in 6-well plates were trans-
fected with ALK4(TD) or ALK7(TD) along with pcDNA3 (V), Flag-Smad2 (2), or Flag-Smad3 (3). Whole cell protein lysates 






































ALK4(TD) ALK7(TD) BReproductive Biology and Endocrinology 2006, 4:52 http://www.rbej.com/content/4/1/52
Page 7 of 8
(page number not for citation purposes)
dependent and -independent mechanisms to regulate
Fshb transcription [32,33].
Previous experiments indicated that the effects of activin
AB were also augmented by transfected ALK7 [19] and we
observed the same pattern of results in our analyses (data
not shown). Given that activin AB is a heterodimer of the
INHBA and INHBB subunits, it is not immediately obvi-
ous how ALK7 could mediate its response. Activin A (an
INHBA homodimer) appears incapable of binding this
receptor (or does so only weakly [24]), so how is it that in
the context of the activin AB heterodimer, the INHBA sub-
unit acquires the ability to bind to one of the two ALK7
proteins contained within the receptor complex? Perhaps
endogenous ALK4 expressed within the cell lines is suffi-
cient to partner with exogenous ALK7; alternatively, con-
formational changes in the INHBA subunit, when
partnered with INHBB, may allow it to interface more effi-
ciently with ALK7. The results of future crystallographic
and mutagenic studies will no doubt clarify the basis for
specificity and flexibility in activin/type I receptor interac-
tions.
ALK2, also known as ActRIA or ACVR1, was initially char-
acterized as an activin type I receptor based on its ability
to bind iodinated activin A in transfection/binding studies
[17]. However, subsequent investigations failed to show
that ALK2 was capable of propagating activin A signals
[15] and here we similarly see that this receptor does not
transduce activin A or B signals to the Fshb promoter. In
fact, ALK2 over-expression actually inhibits the actions of
both ligands, likely because it can bind them but not
propagate their signals. In this way, ALK2 can function as
a dominant-negative regulator of activin action in a man-
ner analogous to that observed with kinase-deficient
forms of ALK4 and ALK7. Interestingly, though not
directly involved in activin signaling, ALK2 is expressed in
LβT2 cells and may play a role in Fshb transcription by
transducing BMP signals [9].
Although ALK7, like ALK4, can clearly propagate activin B
signals, we have yet to demonstrate a physiological role
for this receptor in Fshb regulation. Whereas ALK7 mRNA
is expressed in LβT2 cells and in the adult pituitary, we
must confirm its expression in gonadotropes of the latter.
Even if expressed in these cells, it is not clear that it will be
required for FSH synthesis as ALK7-/- mice are both viable
and fertile [34]. ALK4  is expressed in gonadotropes
[5,35,36] and can mediate activin B signaling in this sys-
tem as shown here. Therefore, ALK4 could compensate for
the loss of ALK7 in these and other cells [34].
Conclusion
Collectively, the data suggest that while ALK7 can propa-
gate activin B signals to regulate Fshb promoter activity,
ALK4 may be the preferred receptor for this ligand, as it is
for activin A. Ultimately, ablation of ALK4  and  ALK7
alone and together within gonadotropes will be necessary
to determine their relative roles in mediating activin B-
regulated FSH synthesis in vivo.
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